Max Bayer

Industry analyst Gabrielle Masson and expert Max Bayer discuss the surge in biopharma layoffs in Q1 2024, analyzing the reasons behind this trend. They also highlight positive industry developments amidst the challenges faced by companies. The podcast explores investment dynamics, job market realities, and the shift towards cautious expansion in the biopharma sector.

Biotech industry analyst Annalee Armstrong and expert Max Bayer dive into the top money raisers in biotech for 2023. They discuss funding trends, the biotech financing landscape, and the stories behind the numbers. From the rise of dual-track processes to strategic partnerships and upcoming biotech IPOs, this episode is a must-listen for industry enthusiasts.

Fierce Biotech's Max Bayer interviews Verve Therapeutics' CEO Sekar Kathiresan, M.D. They discuss Verve's lead program for genetic high cholesterol, their gene therapy programs, hurdles faced, and the potential of base editing technology. They also explore Dr. Kathiresan's transition to biotech after 20+ years as a cardiologist and geneticist.